Current Issue : October-December Volume : 2018 Issue Number : 4 Articles : 2 Articles
Nimodipine is dihydropyridine calcium channel blocker, generally used for the treatment of high blood pressure. It has shown the good results in preventing major issues of subarachnoid hemorrhage (a form of cerebral hemorrhage) termed vasospasm; this is currently the main use of nimodipine. In the present study buccal drug delivery of nimodipine was developed. Matrix type of buccal patches was developed by using polymers HPMC K4M, HPMC K15M and HPMC K100M, sodium alginate and PVP K 30. Buccal patches were formulated by employing solvent casting method. Drug and excipient compatibility studies were implemented by using FTIR, DSC and no interaction was observed. Formulations were prepared with the different concentrations of polymers from the F1-F9, all the formulated patches were evaluated for the various physical parameters like physical appearance, flatness, thickness, weight variation, drug content, moisture absorption, moisture loss, swelling study, folding endurance and all the results were obtained within the pharmacopeial limits. In in-vitro drug release studies by using dialysis membrane, among all the 9 formulations F7 formulation which contain HPMC K100M 175 mg had shown 97.57% cumulative drug release within 12 hours. For F7 formulation release kinetics was plotted and the regression coefficient value was found to be high for Pappas release model was 0.991....
Vaginal route is one of the underutilized route of administration which is known since ancient time, but nowadays it is gaining importance because of advanced formulation technologies which include effervescent technology, Bio-adhesive technology and vaginal rings. Vaginal route remains a promising route when the drug undergoes gastric disintegration (Progesterone) and hepatic first pass (Estrogen). But VDDS remains less patient compliance compared to other routes so newer formulation techniques are required to ensure increased patient compliance....
Loading....